Clinical trials: Non-small Cell Lung Carcinoma
Lung Cancer
Iscar for Supplemental Care in Stage IV Lung Cancer
The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy.
- Trial name
- NCT00079794
- Testing
- Iscar, mistletoe
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Non-small Cell Lung Cancer
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an…
- Trial name
- NCT02463994
- Testing
- MPDL3280A, Hypofractionated Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
Carcinoma, Non-Small-Cell Lung
Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
- Trial name
- NCT00061646
- Testing
- ABT-510/Thrombospondin-1 mimetic, Carboplatin/Taxol
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
- Trial name
- ATLANTIC (NCT02087423)
- Testing
- MEDI4736
- Where
- 139 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- AstraZeneca
NSCLC, Stage III
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.
- Trial name
- NCT05611879
- Testing
- Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC), Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
NSCLC, Stage I, II, IIIA, IIIB, Surgery
Pronostic and Predictive Value of EMT in Localized Lung Cancer
The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC.
- Conditions
- NSCLC, Stage I, II, IIIA, IIIB, Surgery, Progression, Epithelial Mesenchymal Transition
- Trial name
- TWISTlung (NCT03509779)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- European Georges Pompidou Hospital
Advanced Non-small Cell Lung Cancer
The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab
For patients with nonsquamous NSCLC and a good performance status (PS), pemetrexed and cisplatin has been recommended for first-line NSCLC treatment.
- Trial name
- NCT02200354
- Testing
- pemetrexed with bevacizumab
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kobe City General Hospital
Non-Small-cell Lung Cancer
Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer
Rationale: With 1.6 million new cases diagnosed each year and 1.3 million deaths, lung cancer is the leading cancer-related death worldwide and it represents a pressing health issue.
- Trial name
- NCT01885754
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Non-small Cell Lung Cancer
The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer
The trial evaluates the utility of 18FDG-PET/CT scan in the target definition process when SBRT is planned for stage I NSCLC.
- Trial name
- NCT00380666
- Testing
- PET/CT scan
- Sponsor
- University of Aarhus
Locally Advanced Non-small Cell Lung Cancer
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.
- Trial name
- NSCLC (NCT01059552)
- Testing
- vorinostat
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Fox Chase Cancer Center
Non Small Cell Lung Cancer
The Canada Lymph Node Score: A Feasibility Randomized Controlled Trial
For patients diagnosed with early stage Non-Small Cell Lung Cancer (NSCLC) on preoperative computerized tomography (CT) and positron emission tomography (PET) scans, surgical resection is usually the preferred method of…
- Trial name
- CLNS (NCT03859349)
- Testing
- Selective Targeted Sampling, Systematic Sampling
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Non-small Cell Lung Cancer
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic…
- Trial name
- NCT04656652
- Testing
- DS-1062a, Docetaxel
- Where
- 209 sites in United States, Argentina and 24 more
- Volunteers
- 605 people
- Sponsor
- Daiichi Sankyo
Non-small Cell Lung Cancer
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Lung cancer (LC) is the tumor responsible for the highest mortality worldwide. Lung adenocarcinoma is the major subtype of lung cancer and represents the deadliest human cancer, affecting current-, ex-, and even non-smokers.
- Trial name
- OSIREAL (NCT06068049)
- Where
- 26 sites in Spain
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
This randomized phase I trial is studying the side effects and the best dose of selumetinib when given together with paclitaxel as a second line therapy in treating patients with stage IIIB-IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT02503358
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Carcinoma，Non-Small-Cell Lung
Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment
The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in [14C] AC0010 ADME.
- Trial name
- NCT03053219
- Testing
- AC0010
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Advanced Solid Tumor, Non-small Cell Lung Cancer
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced…
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT05780307
- Testing
- IMM2520
- Where
- China
- Volunteers
- 48 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases
- Trial name
- NCT02804100
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wenzhou Medical University
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study.
- Conditions
- Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT03401385
- Testing
- Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
- Where
- 18 sites in United States, Japan
- Volunteers
- 890 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.